Abstract 4482
Background
Cancer and the adverse events of its treatment influence patients’ psychology and decrease their quality of life. The aim of this study was the investigation of the relationship between anxiety, depression and quality of life of ambulatory cancer patients undergoing chemotherapy.
Methods
This cross-sectional study was conducted in the one-day clinic of a large anticancer Hospital in Athens, Greece. Our convenience heterogeneous sample included 150 patients who received chemotherapy. Participants completed the Distress Thermometer and Problem List, the Hospital Anxiety and Depression Scale (HADS), the EORTC QLQ-C30 (version 3.0) for the assessment of Quality of life and the demographic and clinical characteristics questionnaire. Permission for the research was obtained by the ethical committee of the hospital. Data analysis was conducted by SPSS 22.0. The statistical significance level was set at p < 0.05.
Results
The mean age of the participants was 60.07±11.42 while 64% of the sample was female. The majority of patients reported worry (82.7%), fatigue (84.7%), fear (74.7%), nervousness, (51.3%) sadness (51.3%) and depression (34%). Female patients reported higher distress levels than male (p < 0,005). The participants’ educational level was found to correlate significantly with the cognitive functioning (p = 0.017) and financial impact (p = 0.026) subscales. Statistically significant positive correlations were found between HADS-anxiety and HADS-depression and symptom subscales of the EORTC QLQ-C30 questionnaire (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbances, appetite loss and financial impact). Statistically significant negative correlations were also found between HADS-anxiety and HADS-depression and the functional subscales of the EORTC QLQ-C30 questionnaire (physical, role, emotional, cognitive and social functioning).
Conclusions
Anxiety and depression have a negative influence on the quality of life of ambulatory cancer patients during chemotherapy. Nurses could play an important role in the recognition and management of these symptoms. Academics and nurse managers professionals need to enhance nurses’ knowledge and sensitivity and empower them to take an active role.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Program of Postgraduate Studies in "Neurological Disorders - Evidence Based Practice", Nursing Department, University of West Attica, Athens, Greece.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract